Allstocks.com's Bulletin Board Post New Topic  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » NASDAQ, AMEX, NYSE Stocks » CBLI - Cleveland BioLabs Inc.

 - UBBFriend: Email this page to someone!    
Author Topic: CBLI - Cleveland BioLabs Inc.
DallasInvestor
Member


Rate Member
Icon 1 posted      Profile for DallasInvestor     Send New Private Message       Edit/Delete Post   Reply With Quote 
Company Appears to Have Great Potential

Cleveland BioLabs will be presenting at the 2007 Robins Emerging Opportunities Conference to be held in New York City, next thursday, May 24th.

It is always encouraging to see a Company, take the opportunity to increase public visibility, regarding product developments.

CBLI is developing for Commercialization Two Prospective Drugs that Appear to Hold Promise

Protectan CBLB 502 - modified protein of a microbe that protect cells from apoptosis, and which therefore have a broad spectrum of potential applications, including protection from exposure to radiation (whether as a result of military or terrorist action or as a result of a nuclear accident), as well as medical applications such as reducing cancer treatment side effects.

Curaxins CBLC102 - small molecule designed to kill tumor cells by simultaneously targeting two regulators of apoptosis. It can be effective against a number of malignancies, including renal cell carcinoma, soft-tissue sarcoma and hormone refractory prostate cancer. Curaxin CBLC102, enters Phase II human trials in patients with androgen-independent (hormone refractory) prostate cancer in July 2006.

Posts: 56 | From: Dallas, TX | Registered: Oct 2006  |  IP: Logged | Report this post to a Moderator
DallasInvestor
Member


Rate Member
Icon 1 posted      Profile for DallasInvestor     Send New Private Message       Edit/Delete Post   Reply With Quote 
Shares Move Up Nicely Today, as New Breakthroughs for CBLI Compound Announced

Today’s news is very exciting.

In addition to efficacy in stimulation and mobilization of stem cells, Protectan CBLB612 has demonstrated both radiation protection and mitigation properties over a very broad time window of use.

In animal experiments, Protectan CBLB612 has produced complete and sustained recovery of the blood production system following lethal doses of radiation.

Posts: 56 | From: Dallas, TX | Registered: Oct 2006  |  IP: Logged | Report this post to a Moderator
DallasInvestor
Member


Rate Member
Icon 1 posted      Profile for DallasInvestor     Send New Private Message       Edit/Delete Post   Reply With Quote 
Looks Like Lots of Opportunity, as Compound Showing Effectiveness

Protectan CBLB612 Showing Effectiveness as a Stem Cell Compound

Cleveland BioLabs reported that a study for Protectan CBLB612 showed blood from healthy mice treated with the drug, helped mice who were issued a normally lethal dose of radiation survive past the 60-day mark.

The company said the experiment demonstrated effectiveness in stimulation and mobilization of stem cells.

Posts: 56 | From: Dallas, TX | Registered: Oct 2006  |  IP: Logged | Report this post to a Moderator
DallasInvestor
Member


Rate Member
Icon 1 posted      Profile for DallasInvestor     Send New Private Message       Edit/Delete Post   Reply With Quote 
Conference Call Tomorrow

Robins Group Conference

Company Webcast Tomorrow – Thursday – 11:30 AM Eastern

The Robins Group Emerging Opportunities Conference Webcast

When: May 24, 2007 * 11:30 AM Eastern

Where: http://www.vcall.com/CEPage.asp?ID=117098

How: Live over the Internet -- Simply log on to the web at the address above.

Contact: Connie Schadewitz, (360)828-8601 or connie*catalyst-system.com

If you are unable to participate during the live webcast, the call will be available for replay at http://www.vcall.com/ClientPage.asp?ID=117098 or http://www.investorcalendar.com/

Posts: 56 | From: Dallas, TX | Registered: Oct 2006  |  IP: Logged | Report this post to a Moderator
DallasInvestor
Member


Rate Member
Icon 1 posted      Profile for DallasInvestor     Send New Private Message       Edit/Delete Post   Reply With Quote 
Nice Rise Friday, Up 2 Percent

CBLI shares advanced Two Percent Friday, as the Company spoke to the Investment Community the previous day, at The Robins Group Conference.

Key for any Research and Development Biotechnology firm is to increase awareness of the important work that is taking place at the firm.

This Company clearly appears to have an exciting story to tell regarding health discoveries. Cleveland BioLabs is leveraging its discoveries to develop drug candidates impacting Biodefense, Cancer Treatment, and Tissue Protection. Specifically, the Science targets programmed cell death (apoptosis) by developing drugs which switch apoptosis on and off.

Posts: 56 | From: Dallas, TX | Registered: Oct 2006  |  IP: Logged | Report this post to a Moderator
DallasInvestor
Member


Rate Member
Icon 1 posted      Profile for DallasInvestor     Send New Private Message       Edit/Delete Post   Reply With Quote 
Thursday - NYC Investor Conference

Shares Stayed in Positive Territory Today, Ahead of This Week’s Investor Conference in NYC on Thursday.

The Company is scheduled to present at the Friedman, Billings, Ramsey & Co., Inc. 2007 Growth Conference to be held at The Grand Hyatt New York in New York City, May 30-31.

Michael Fonstein, Ph.D., President and Chief Executive Officer of Cleveland BioLabs, will give a presentation on the Company followed by a question and answer session on May 30, at 8:15 a.m. EDT. The presentation will be broadcast live over the Internet and archived for three months. Interested parties may tune in to the live presentation by visiting the Company's website at: www.cbiolabs.com.

Posts: 56 | From: Dallas, TX | Registered: Oct 2006  |  IP: Logged | Report this post to a Moderator
DallasInvestor
Member


Rate Member
Icon 1 posted      Profile for DallasInvestor     Send New Private Message       Edit/Delete Post   Reply With Quote 
Company Presentation Today

CBLI is set to Present at the Friedman, Billings, Ramsey & Co. Inc. Conference Today.

Cleveland BioLabs recently announced the results of a study of the efficacy of Protectan CBLB612, one of its radiation protectors, in an animal bone marrow stem cell transplantation model. Peripheral blood from CBLB612-treated donors rescued 100% of lethally irradiated mice from bone marrow deficiency. The rescuing effect of the peripheral blood of the treated mice was equivalent to that of conventional bone marrow transplantation.

The Company has two lead compounds in late stages of development. Curaxin CBLC102 is an orally administered small molecule designed to kill tumor cells by simultaneously targeting two key regulators of apoptosis. The Company has an ongoing Phase II trial with CBLC102 in hormone refractory prostate cancer.

Posts: 56 | From: Dallas, TX | Registered: Oct 2006  |  IP: Logged | Report this post to a Moderator
DallasInvestor
Member


Rate Member
Icon 1 posted      Profile for DallasInvestor     Send New Private Message       Edit/Delete Post   Reply With Quote 
Cancer Treatment and Radiation Protection

Cleveland BioLabs, Inc. (CBLI) is developing new types of drugs for cancer treatment and the protection of normal tissues from radiation.

The Company has 24 employees, working in its fully-equipped research facility located near the Cleveland Clinic and the campus of Case Western Reserve University.

CBL concentrates on the development of small molecule drugs and biologics focusing on two major therapeutic directions:

The focus is the development of drugs that protect normal tissues from the damaging effects of ionizing radiation and chemotherapy (Protectans).

This is further branched into: development of radioprotectants for non-medical applications, e.g., protection against the military or terrorist use of nuclear weapons; and development of cancer treatment supplements that decrease the side effects of radiation treatment and anticancer drugs and allow for an increased dose of radiation and anticancer drugs to be safely received by a patient.

Another goal is the development of anticancer drugs targeting a newly discovered way of regulating cell death (Curaxins).

Posts: 56 | From: Dallas, TX | Registered: Oct 2006  |  IP: Logged | Report this post to a Moderator
DallasInvestor
Member


Rate Member
Icon 1 posted      Profile for DallasInvestor     Send New Private Message       Edit/Delete Post   Reply With Quote 
Recent Coverage on Firestocks

Recently, CBLI was covered in depth in a Corporate Update Report, as seen on Firestocks.com

The video highlights the great strides made by the Company, to date, in solidifying its
preeminent position in the field of cancer research and treatment. Study data continues to show positive results and efficacy for their potential drug therapies.

From an Initial Price of $5.10, the shares have been trading above $9.00.

In the video, the host interviews Stephen Brozak, the WBB Securities Analyst, who set a “BUY” Rating and a 12 month Target Price for the shares at $13.00.

Posts: 56 | From: Dallas, TX | Registered: Oct 2006  |  IP: Logged | Report this post to a Moderator
DallasInvestor
Member


Rate Member
Icon 1 posted      Profile for DallasInvestor     Send New Private Message       Edit/Delete Post   Reply With Quote 
The Science makes sense at CBLI

Recent analyst comments suggest that the financial prospects for CBLI appear to have a strong upside.

The Company’s pre-clinical studies appear to make sense. They have shown their ability to meet un-met needs in the fields of radiation protection, as well as transplantation protocols specific to regenerative stem cell transplant therapy.

In addition, the Company appears well positioned in the field of HHS and DOD Federal Government Contracting. If successful in contract awards, the revenue potential could be $200 million.

The CBLI product candidate is unique in that it protects against both Gastrointestinal as well as Hematopoetic radiation induced damage.

Posts: 56 | From: Dallas, TX | Registered: Oct 2006  |  IP: Logged | Report this post to a Moderator
DallasInvestor
Member


Rate Member
Icon 1 posted      Profile for DallasInvestor     Send New Private Message       Edit/Delete Post   Reply With Quote 
Gov't Contracting May Hold a Key

Government Contracting May be One Avenue of Success for CBLI

Over the last couple of days, the shares have been quietly moving upward, as the Company Continues its Important Work

The Analyst with WBB Securities indicated that the potential for Government Contracting Awards is a viable one. He indicated that the potential of Government Contract Awards played a partial role in his evaluation of CBLI. If the Company is successful in that area, the financial impact can be large.

The Company’s pre-clinical studies appear to make sense. They have shown their ability to meet un-met needs in the fields of radiation protection, as well as transplantation protocols specific to regenerative stem cell transplant therapy.

Posts: 56 | From: Dallas, TX | Registered: Oct 2006  |  IP: Logged | Report this post to a Moderator
DallasInvestor
Member


Rate Member
Icon 1 posted      Profile for DallasInvestor     Send New Private Message       Edit/Delete Post   Reply With Quote 
CBLB502 is the Company’s Radiation Antidote

Cleveland BioLabs Protectan CBLB502 Demonstrated Strong Survival Benefits as a Mitigator against Radiation-Induced Damage in Study

CBLB502 is the first compound to provide protection from both gastrointestinal and hematopoietic radiation-induced damage when administrated before or after irradiation. Moreover, mitigation shown in two animal species opens much broader potential markets for CBLB502's use as a radiation antidote."

The Company is submitting Protectan CBLB502 to the Department of Defense (DoD) in response to a recently published Request for Proposal (RFP) for medical radiation countermeasures to treat gastrointestinal effects of acute radiation syndrome. The RFP award would provide funding for development of the countermeasure through FDA approval, as well as a commitment to purchase up to 500,000 doses, thereafter.

Protectan CBLB502 is undergoing an accelerated development program under the FDA two-animal rule, which requires the Company to show efficacy in two animal species and only safety in humans. Cleveland BioLabs is in the process of completing Good Manufacturing Practices compliant (cGMP) manufacturing of Protectan CBLB502 and plans to submit an Investigational New Drug (IND) application for a human safety study later this year.

Posts: 56 | From: Dallas, TX | Registered: Oct 2006  |  IP: Logged | Report this post to a Moderator
DallasInvestor
Member


Rate Member
Icon 1 posted      Profile for DallasInvestor     Send New Private Message       Edit/Delete Post   Reply With Quote 
Study Continues to Show Efficacy

Protectan CBLB612 Contines to Show Efficacy in the Field of Stem Cell Transplantation and Regenerative Medicine

"We are very excited about the results we have achieved to date in our studies of Protectan CBLB612 as an effective producer of long-term adult bone marrow stem cells in peripheral blood. The transplant study in particular, has advanced our research into clinical applications and suggests multiple potential uses within the field of regenerative medicine."

Adult hematological bone marrow stem cell transplantation is currently used for hematological disorders (malignant and non-malignant), as well as some non-hematological diseases, such as breast cancer, testicular cancer, neuroblastoma, ovarian cancer, Severe Combined Immune Deficiency (SCID), Wiskott-Aldrich syndrome, and Chediak-Higashi syndrome.

Administration of Protectan CBLB612 increases the level of a number of cytokines known to stimulate blood regeneration. This compares to the current clinical practice of administering a single purified cytokine, such as G-CSF (Neupogen®, Granocyte®, Neulasta®). Protectan CBLB612 stimulates production of adult bone marrow stem cells through multiple mechanisms, making it potentially more effective than currently used clinical protocols. In addition, Protectan CBLB612 could be used in treating those individuals that do not respond to G-CSF.

In addition to efficacy in stimulation and mobilization of stem cells, Protectan CBLB612 has demonstrated both radiation protection and mitigation properties over a very broad time window of use. In animal experiments, Protectan CBLB612 has produced complete and sustained recovery of the blood production system following lethal doses of radiation.

Posts: 56 | From: Dallas, TX | Registered: Oct 2006  |  IP: Logged | Report this post to a Moderator
DallasInvestor
Member


Rate Member
Icon 1 posted      Profile for DallasInvestor     Send New Private Message       Edit/Delete Post   Reply With Quote 
Cancer Stocks Represent an Important and Viable Niche Sector

Analysts noted that many Cancer related stocks advanced in early June, as presentations began at the American Society of Clinical Oncology which was meeting in Chicago.

CBLI is clearly one emerging firm, with three key products in development, that hold promise.

Cleveland BioLabs recently announced the results of a study of the efficacy of Protectan CBLB612, one of its radiation protectors, in an animal bone marrow stem cell transplantation model. Peripheral blood from CBLB612-treated donors rescued 100% of lethally irradiated mice from bone marrow deficiency. The rescuing effect of the peripheral blood of the treated mice was equivalent to that of conventional bone marrow transplantation.

The Company has two lead compounds in late stages of development. Curaxin CBLC102 is an orally administered small molecule designed to kill tumor cells by simultaneously targeting two key regulators of apoptosis. The Company has an ongoing Phase II trial with CBLC102 in hormone refractory prostate cancer.

Cleveland BioLabs' other lead compound, Protectan CBLB502, is a modified protein of a microbe that protects cells from regulated cell death. The Company recently submitted CBLB502 to the Department of Defense in response to a Request for Proposal (RFP) for medical radiation countermeasures to treat gastrointestinal effects of acute radiation syndrome. The RFP award would provide funding for development of the countermeasure through FDA approval, as well as a commitment to purchase up to 500,000 doses, thereafter.

Posts: 56 | From: Dallas, TX | Registered: Oct 2006  |  IP: Logged | Report this post to a Moderator
DallasInvestor
Member


Rate Member
Icon 1 posted      Profile for DallasInvestor     Send New Private Message       Edit/Delete Post   Reply With Quote 
The Shares Rebounded Today, with Solid Volume; as Company Reports Investment Visibility

CBLI reported that it will join the Russell Microcap(TM) Index when Russell Investment Group reconstitutes its family of U.S. indexes on June 22, according to a preliminary list of additions posted Friday on www.russell.com.

Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes.

Dr. Michael Fonstein, Chief Executive Officer and President of Cleveland BioLabs, stated, "Our addition to the Index is reflective of the Company's significant growth and development since our IPO last year. We look forward to increased visibility resulting from our inclusion."

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. An industry-leading $4 trillion in assets currently are benchmarked to them.

Posts: 56 | From: Dallas, TX | Registered: Oct 2006  |  IP: Logged | Report this post to a Moderator
DallasInvestor
Member


Rate Member
Icon 1 posted      Profile for DallasInvestor     Send New Private Message       Edit/Delete Post   Reply With Quote 
Listing in Russell Microcap™ Index is Very Good News

Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. An industry-leading $4 trillion in assets currently are benchmarked to them.

Annual reconstitution of Russell indexes captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization to create the Russell 3000® Index and Russell Microcap.

With more than $200 billion in assets under management, Russell serves individual, institutional and advisor clients in more than 40 countries. Russell provides access to some of the world's best money managers. It helps investors put this access to work in corporate defined benefit and defined contribution plans, and in the life savings of individual investors.

Posts: 56 | From: Dallas, TX | Registered: Oct 2006  |  IP: Logged | Report this post to a Moderator
DallasInvestor
Member


Rate Member
Icon 1 posted      Profile for DallasInvestor     Send New Private Message       Edit/Delete Post   Reply With Quote 
Shares Up Very Strong Friday

Shares Up 51 cents on Friday, for a Gain on the Day of 5.10 Percent.

I recently noticed the Walter Ramsley’s Special Situation Letter from February 2007 that talks in some detail regarding the Military Application. I found it interesting reading.


The letter noted that, “Cleveland BioLabs is a leading provider of antidotes that protect soldiers and civilians from nuclear fallout.

Radiation from dirty bombs and nuclear accidents can inflict widespread casualties that are difficult to treat with existing medical care. Gamma rays kill healthy cells, particularly in the blood system and gastro-intestinal tract. Damage correlates to the degree of exposure (intensity and time).

Death rates increase as the ill effects accumulate. Cleveland BioLabs has developed a technology that can manipulate the process which controls cell death (“apoptosis”). Its lead drug (“CBLB502”) shields bone marrow, blood, and gastro-intestinal cells from the effect of gamma rays, enabling them to resist the onslaught.

The compound made mice virtually indestructible. In primate tests, 70% survived extremely high radiation exposure. The other 30% lived longer than the control group, suggesting it might be possible to save more victims with additional treatment.

The drug also was shown safe to be consumed in limited human studies. (Ethical rules prohibit people from actually being exposed to radiation.)

The U.S. military is likely to be the company’s first customer.

Cleveland BioLabs has been working in cooperation with the Department of Defense to engineer a practical solution.

In fact, Pentagon grants have helped finance much of the work. Soldiers will be able to inject the drug themselves with a regular syringe.

No refrigeration is needed. No specialized medical personnel are required. Soldiers can inject the drug either before or after they are exposed.

The dosage contemplated protects for 2-3 hours at the highest radiation levels, allowing units to keep performing under otherwise lethal conditions. The drug is expected to work effectively for 10-15 hours at locations that are somewhat removed from the immediate blast site.

People who are exposed to radiation can take the drug afterward and minimize the damage.

Animal testing indicates that multiple doses are possible. Performance is just as good on the second or third shot as the first.”

Posts: 56 | From: Dallas, TX | Registered: Oct 2006  |  IP: Logged | Report this post to a Moderator
DallasInvestor
Member


Rate Member
Icon 1 posted      Profile for DallasInvestor     Send New Private Message       Edit/Delete Post   Reply With Quote 
Department of Defense Contracts May Hold the Key

In March, Cleveland BioLabs received a contract from the Defense Threat Reduction Agency (DTRA) of the Department of Defense (DoD) to fund "development leading to the acquisition" of Protectan CBLB502, in collaboration with the Armed Forces Radiobiology Research Institute (AFRRI), which has also received significant independent funding for work on Protectan CBLB502.

In April, Cleveland BioLabs, Inc. , responded to an additional Request for Proposal (RFP) issued in March 2007, by The Department of Defense (DoD) for the Advanced Development of Medical Radiation Countermeasures (MRC) to treat gastrointestinal effects of acute radiation syndrome (ARS). It is expected that the RFP may be awarded later in the year.

The objective of the RFP is to develop a post-exposure Medical Radiation Countermeasure through approval/licensure with the U.S. Food and Drug Administration (FDA) and procure quantities sufficient to achieve Initial Operational Capability (IOC). A range of 50,000 to 500,000 doses was specified. The RFP award would provide funding for development of the countermeasure through FDA approval, as well as a commitment to purchase, thereafter.

Posts: 56 | From: Dallas, TX | Registered: Oct 2006  |  IP: Logged | Report this post to a Moderator
DallasInvestor
Member


Rate Member
Icon 1 posted      Profile for DallasInvestor     Send New Private Message       Edit/Delete Post   Reply With Quote 
Shares Continue on Recent Upward Trend

Up an Additional 2 Percent Today

The recent Bone Marrow Stem Cell Transplantation Study suggests multiple potential uses for CBLB612.

Blood from healthy mice treated by Protectan CBLB612 was transplanted into mice that received a lethal dose of radiation that killed hematopoietic (bone marrow/blood production) stem cells. A small amount of blood from the CBLB612 treated mice successfully rescued the mice with radiation-induced bone marrow stem cell deficiency. 100% of the deficient mice transplanted with blood from CBLB612 treated mice survived past the 60-day mark, while 85% of the untreated deficient mice died within the first three weeks of the experiment. The 60- day mark is considered to be the critical point in defining the presence of long-term adult bone marrow stem cells, which are capable of completely restoring lost or injured bone marrow function. The rescuing effect of the peripheral blood of the treated mice was equivalent to that of conventional bone marrow transplantation.

Cleveland BioLabs President and Chief Executive Officer, Michael Fonstein, Ph.D., commented, "We are very excited about the results we have achieved to date in our studies of Protectan CBLB612 as an effective producer of long-term adult bone marrow stem cells in peripheral blood. The transplant study in particular, has advanced our research into clinical applications and suggests multiple potential uses within the field of regenerative medicine."

Posts: 56 | From: Dallas, TX | Registered: Oct 2006  |  IP: Logged | Report this post to a Moderator
DallasInvestor
Member


Rate Member
Icon 1 posted      Profile for DallasInvestor     Send New Private Message       Edit/Delete Post   Reply With Quote 
Curaxin CBLC102 Holds Promise for the Treatment of Prostate Cancer

Curaxin CBLC102 is a safe, oral drug used in the past to treat malaria that demonstrates efficacy in vitro, in animal models, and in live tumors removed from patients. Initial test results indicate that CBLC102 can be effective against a number of malignancies, including hormone refractory prostate cancer, renal cell carcinoma (a highly fatal form of kidney cancer), and soft-tissue sarcoma. The FDA permitted Cleveland BioLabs to advance directly to Phase II studies, based on CBLC102's historic safety profile. The Company has a "method of use" patent application pending on Curaxin CBLC102.


Last December, the Company began its Phase II efficacy study for Curaxin CBLC102 in advanced, hormone-refractory (androgen independent) prostate cancer at the Cleveland Clinic and Case Western Reserve University Hospital

Posts: 56 | From: Dallas, TX | Registered: Oct 2006  |  IP: Logged | Report this post to a Moderator
DallasInvestor
Member


Rate Member
Icon 1 posted      Profile for DallasInvestor     Send New Private Message       Edit/Delete Post   Reply With Quote 
CBLI Gaining Upward Share Price Momentum, as Investors are Responding

Tomorrow, June 22nd is a key date. It was previously reported that CBLI will join the Russell Microcap Index when Russell Investment Group reconstitutes its family of U.S. indexes on June 22nd.

Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. An industry-leading $4 trillion in assets currently are benchmarked to them.

Russell Investment Group aims to improve financial security for people by providing strategic advice, world-class implementation, state-of-the-art performance benchmarks, and a range of institutional-quality investment products.

Posts: 56 | From: Dallas, TX | Registered: Oct 2006  |  IP: Logged | Report this post to a Moderator
DallasInvestor
Member


Rate Member
Icon 1 posted      Profile for DallasInvestor     Send New Private Message       Edit/Delete Post   Reply With Quote 
Shares Lift Off Today, Up 5.17% to Close at $11.40

230,855 Shares Traded Today

CBLI Featured in Business Week

The article goes on to say,

“The military may be the first customer of little-known Cleveland BioLabs Inc. (CBLI) for its radiation protection compound called Protectan or CBLB502.

The company had responded to a Defense Dept. Request for Proposal in April. "It is likely Cleveland BioLabs will get a government contract for its product by summer's end," says Stephen Brozak of WBB Securities, who rates the stock a buy. It has rocketed from 4.80 in September, when it was first featured in this column, to 10.59 on June 20.

Brozak says no other product offers the same level of protection from radiation exposure. CEO Michael Fonstein says Protectan has the ability to mitigate the damaging effects of ionizing radiation on the gastrointestinal system and shows significant survival benefits suited to the Defense Dept.'s requirements.

Brozak says the contract could go as high as $200 million based on similar awards.

Walter Schenker of Titan Capital Management, which owns shares, says Protectan has shown effectiveness against radiation when applied two hours prior to exposure or up to eight hours after”

Posts: 56 | From: Dallas, TX | Registered: Oct 2006  |  IP: Logged | Report this post to a Moderator
DallasInvestor
Member


Rate Member
Icon 1 posted      Profile for DallasInvestor     Send New Private Message       Edit/Delete Post   Reply With Quote 
Business Week Features CBLI

The CLBI Defense Related Article in Business Week’s July 2nd Issue Definitely Increases the Company Visibility

The article goes on to say, “The military may be the first customer of little-known Cleveland BioLabs for its radiation protection compound called Protectan or CBLB502. The company had responded to a Defense Dept. Request for Proposal in April. "It is likely Cleveland BioLabs will get a government contract for its product by summer's end," says Stephen Brozak of WBB Securities, who rates the stock a buy.

Posts: 56 | From: Dallas, TX | Registered: Oct 2006  |  IP: Logged | Report this post to a Moderator
DallasInvestor
Member


Rate Member
Icon 1 posted      Profile for DallasInvestor     Send New Private Message       Edit/Delete Post   Reply With Quote 
Saw this on another Board……….

Roswell Park Boosts Life Sciences Economy

BUFFALO, NY- What a banner year it has been so far for Roswell Park Cancer Institute (RPCI). Since the beginning of 2007, the Institute has announced that a highly accomplished cancer researcher and his biomedical company are relocating to Buffalo, and that RPCI laboratory discoveries have led to the creation of a new life sciences spin-off company in Buffalo.

Distinguished national leader, Dr. Andrei Gudkov, joins RPCI.
The world-renowned researcher is Andrei V. Gudkov, PhD, from the Cleveland Clinic, and the biomedical company is Cleveland BioLabs, Inc. ­– the drug discovery and development company he founded in 2003.

Dr. Gudkov will assume senior leadership roles at Roswell Park and Cleveland BioLabs will partner with Roswell Park to further invigorate the biomedical environment on the Buffalo Niagara Medical Campus. The moves will bring up to 50 advanced research positions to Buffalo.

“Dr. Gudkov is a pre-eminent researcher, and his company has an extensive pipeline of cancer and radioprotectant drug candidates in advanced development that hold the promise of helping patients worldwide,” according to David C. Hohn, MD, president & CEO at Roswell Park. “The presence of Dr. Gudkov and his company can only enhance the ability of Roswell Park and its partners on the Buffalo Niagara Medical Campus to attract the talent needed to grow the biomedical economy in Western New York.”

Dr. Gudkov will become Senior Vice President for Research Program Development and Chair of the Department of Cell Stress Biology at Roswell Park, as well as leader of the Biophysical Therapies Program and member of Roswell Park’s senior leadership team.

Cleveland BioLabs has entered into a strategic research partnership with Roswell Park as the foundation for advancing research and clinical trials on potential drugs being developed based on Dr. Gudkov’s research. The company will relocate its headquarters and core operations to Buffalo in a facility to be acquired, renovated, and managed by the Buffalo Niagara Medical Campus.

Posts: 56 | From: Dallas, TX | Registered: Oct 2006  |  IP: Logged | Report this post to a Moderator
DallasInvestor
Member


Rate Member
Icon 1 posted      Profile for DallasInvestor     Send New Private Message       Edit/Delete Post   Reply With Quote 
The way I see it ………………

From the way I see it, the stock is just getting profit taking from the strong move over the last week. The dod has not made a decision. If they win and it could come over the summer, some suggest the stock will trade north of 50.

Posts: 56 | From: Dallas, TX | Registered: Oct 2006  |  IP: Logged | Report this post to a Moderator
DallasInvestor
Member


Rate Member
Icon 1 posted      Profile for DallasInvestor     Send New Private Message       Edit/Delete Post   Reply With Quote 
Shares Headed North Again Today

Shares Rebounded Friday, Gaining 2.81%; on Strong Volume of 132k Shares Traded.

I noticed one ****ger on another board, had his take on the recent profit taking. He was saying, “The stock made a major move over the last two weeks on the basis of the Russell rebalancing and the business week article.

When the stock did not push through resistance at 11.98, it was only natural that the day traders and the people who played the Russell rebalancing sold.”

The key here is that the volume has definitely picked up; as CBLI has been getting increased visibility.

Posts: 56 | From: Dallas, TX | Registered: Oct 2006  |  IP: Logged | Report this post to a Moderator
DallasInvestor
Member


Rate Member
Icon 1 posted      Profile for DallasInvestor     Send New Private Message       Edit/Delete Post   Reply With Quote 
CBLI Gets BioTech Exposure

CBLI Cited Sunday July 01,in a BioHealthInvestor.com "Interview: Investment Opportunities in Healthcare with Alan Brochstein". Alan Brochstein is a CFA with AB Analytical Services.

In responding to a question, he noted, "I created a universe of stocks today with all of the U.S. based biotechs with market capitalization in excess of $50mm. It is clear why so many investors are attracted to the market, as the payoffs can be quite extreme. In fact, thus far this year, nine companies have gained in excess of 75%, including Opko Health (OPK), Celsion (CLN), Bionovo (BNVI), Onyx (ONXX), BioSante (BPA), Clevland Biolabs (CBLI), Seattle Genetics (SGEN), Biopure (BPUR) and the infamous Dendreon (DNDN)."

Posts: 56 | From: Dallas, TX | Registered: Oct 2006  |  IP: Logged | Report this post to a Moderator
DallasInvestor
Member


Rate Member
Icon 1 posted      Profile for DallasInvestor     Send New Private Message       Edit/Delete Post   Reply With Quote 
Value Rich Coverage

Cleveland BioLabs is featured on Value Rich (iValueRich.com) and the Spring 2007 Issue of Value Rich Magazine

The article notes, “ Cleveland BioLabs is generating excitement with a potential Department of Defense Contract for its lead radiation compound, an ongoing Phase II clinical trial for its oral anti-cancer compound; and animal data on its stem cell application.”

Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic Foundation, ChemBridge Corporation and the Armed Forces Research Radiobiology Institute.

Posts: 56 | From: Dallas, TX | Registered: Oct 2006  |  IP: Logged | Report this post to a Moderator
DallasInvestor
Member


Rate Member
Icon 1 posted      Profile for DallasInvestor     Send New Private Message       Edit/Delete Post   Reply With Quote 
Shares Were Up Strong after the Holiday; Heading North 4.59 Percent Thursday. I recently noticed some informational Q and A points on the Company website:

1. What is the stock symbol for Cleveland BioLabs, Inc. and which exchanges is the stock listed on?
The stock is listed on the NASDAQ Capital Market under the symbol "CBLI" and the Boston Stock Exchange under the symbol "CFB".

2. Is Cleveland BioLabs, Inc. stock traded on any of the European exchanges?
The stock is not currently listed on any foreign exchange.

3. When did Cleveland BioLabs, Inc. go public? At what price?
The initial public offering was on July 21, 2006 at $6.00 per share of common stock.

4. How many shares are outstanding?
There are 11,826,389 common shares outstanding.

5. Can I purchase share directly from the company?
You must purchase shares through your own brokerage firm.

6. Do you anticipate paying a dividend?
The Board of Directions can decide to pay dividends at its discretion based on the financial condition, results of operation, capital requirements, contractual obligations, and other relevant factors. We do not expect to pay dividends in the first several years following the offering.

7. Does Cleveland BioLabs, Inc. plan on offering a direct investment program?
There is currently no direct investment program.

8. Who were the underwriters for the Cleveland BioLabs, Inc. IPO?
The initial public offering was underwritten by the following participating firms:


Sunrise Securities Corp.
Roth Capital Partners


9. Who is the transfer agent?
The transfer agent is:

Continental Stock Transfer & Trust Company.
17 Battery Place
8th Floor
New York, NY 10004
Tel: (212)509-4000
Fax: (212)509-5150


10. Who should I notify to change my mailing address?
An email to our website will handle this.

11. When is the annual stockholder meeting held?
The meeting date has not yet been set, but it will be posted on the website once that happens.

12. What is the fiscal year-end for Cleveland BioLabs, Inc.?
The fiscal year ends on December 31st.

13. How many employees does Cleveland BioLabs, Inc. have?
There are currently 24 full-time employees.

14. Can I get an investor's packet or a copy of Cleveland BioLabs, Inc. prospectus?
Please refer to the Investor Relation contact form.

Posts: 56 | From: Dallas, TX | Registered: Oct 2006  |  IP: Logged | Report this post to a Moderator
DallasInvestor
Member


Rate Member
Icon 1 posted      Profile for DallasInvestor     Send New Private Message       Edit/Delete Post   Reply With Quote 
Buffalo Facilities Appear State of the Art

Saw this comment on another message board………The ****ger commented on Gudkov's Buffalo lab and facilities as being state of the art.

He noted, “I have a friend who lives in Buffalo who recently visited Andrei Gudkov's lab and CBLI's future home facility. Gudkov is now the head of cellular stress at Roswell Park Cancer Center as well as being the Chief Scientific Officer for CBLI.

Roswell has a new state of the art facility that any cancer researcher would kill for. CBLI has a similar licensing arrangement with Roswell that they have with the Cleveland Clinic.

CBLI gets exclusive rights to anything Gudkov is working on or collaborates on. His lab will have nearly 40 researchers working and cbli gets full benefit.

In addition Gudkov is now the head of research at Roswell and it has a $125 million budget. This allows him some sway with other world class researchers in his field even though the other labs are not tied direclty to the cbli deal.

This is all in addition to the 30 plus researchers on cbli's employee list. There are very few companies with access to state of the art facilities such as this and also have a market cap below $200 million.

My friend who knows an enormous amount about such due diligence was very impressed. This should provide cbli numerous opportunities to test out their cancer drugs.

Posts: 56 | From: Dallas, TX | Registered: Oct 2006  |  IP: Logged | Report this post to a Moderator
IMAKEMONEY
Member


Icon 1 posted      Profile for IMAKEMONEY     Send New Private Message       Edit/Delete Post   Reply With Quote 
A ONE MAN SHOW!! I LIKE THAT!!!

--------------------
LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT!

Posts: 9276 | From: San Diego CA | Registered: Jul 2006  |  IP: Logged | Report this post to a Moderator
   

Quick Reply
Message:

HTML is not enabled.
UBB Code™ is enabled.

Instant Graemlins
   


Post New Topic  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2021 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share